Screener
Edwards Lifesciences EW Other countries — Tax Credit Carryforward, Valuation Allowance
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:TaxCreditCarryforwardValuationAllowance.
The source filing: Edwards Lifesciences’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001099800-26-000009
| Line item | Carryforward Amount | Valuation Allowance | Net Tax Benefit | Carryforward Period Ends |
|---|---|---|---|---|
| California research expenditure tax credits | $245.3 | — | $245.3 | Indefinite |
| Federal research expenditure tax credits | 8.2 | — | 8.2 | 2025-2034 |
| United States foreign tax credits | 69.5 | (22.3) | 47.2 | 2025-2034 |
| Non-United States tax credits | — | — | — | 2025-2028 |
| Total | $323.0 | $(22.3) | $300.7 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Edwards Lifesciences's other countries — tax credit carryforward, valuation allowance?
- Edwards Lifesciences (EW) reported other countries — tax credit carryforward, valuation allowance of $0 in Q4 2025.
- What does other countries — tax credit carryforward, valuation allowance mean?
- The valuation allowance applied to tax credit carryforwards generated in international jurisdictions. This reflects the management's assessment of the likelihood that these specific tax credits will expire before they can be utilized to offset tax liabilities.
Ask your AI about Edwards Lifesciences's other countries — tax credit carryforward, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude